Physician FAQs

Ziplyft® is a minimally invasive lid treatment (MILT) that uses compression skin-contouring (CoCo) technology to capture, compress, and excise redundant upper-eyelid skin associated with dermatochalasis in a controlled manner. The treatment is designed to support an elegant in-office workflow with minimal bleeding and bruising, quick recovery, limited downtime, and tissue-adhesive closure.

MILT stands for minimally invasive lid treatment. MILT describes the overall treatment experience: an in-office upper-eyelid treatment designed to minimize bleeding, bruising, swelling, recovery time, and downtime while supporting an efficient, streamlined workflow and helping patients return to their normal daily activities quickly.

• An efficient, refined in-office upper-lid treatment workflow
• Controlled skin capture and excision designed to support bilateral symmetry
• Minimal bleeding and bruising
• No cautery or sutures
• Tissue-adhesive closure when appropriate
• Quick recovery with limited downtime, supporting a prompt return to normal daily activities
• A minimally invasive option that complements a physician’s traditional blepharoplasty capabilities

After preoperative marking, redundant upper-eyelid tissue associated with dermatochalasis is captured within the Ziplyft device and compressed. Controlled compression supports hemostasis before a guarded sliding blade is advanced to excise the captured tissue in a smooth, controlled manner. Compression is maintained after excision, then the device is removed and the treatment area is inspected and dried before skin adhesive is applied for closure. The process is repeated on the fellow lid using the preoperative markings and device reference points to support bilateral symmetry.

Ziplyft offers a minimally invasive option for excision of redundant upper-eyelid skin associated with dermatochalasis in appropriately selected patients. It is designed for an elegant in-office setting with minimal bleeding and bruising, no cautery or sutures, and tissue-adhesive closure. Traditional blepharoplasty remains important when a patient requires broader surgical access, more extensive tissue management, external ptosis repair, or other individualized surgical maneuvers.

Yes. Ziplyft clinical study data and supporting outcomes are available separately for physician review.

Patients with dermatochalasis or redundant upper-eyelid skin who are appropriate for functional or cosmetic upper-lid skin excision may be considered for Ziplyft. Final selection remains at the physician’s clinical discretion and should account for anatomy, ocular and medical history, healing risk, medication use, and whether additional eyelid procedures are needed.

Yes. When clinically appropriate, fat can be addressed through a small nasal incision before the Ziplyft device is applied. Ziplyft is used to address redundant upper-eyelid skin associated with dermatochalasis; the extent of any additional tissue management remains at the physician’s discretion.

Ziplyft removes redundant upper-eyelid skin associated with dermatochalasis; it does not correct ptosis by itself. In selected patients, Ziplyft may be paired with an internal ptosis repair, such as a muellerectomy, when the physician determines that combined treatment is appropriate.

Management of anticoagulation remains at the physician’s clinical discretion and should be individualized according to the patient’s medication, medical history, bleeding risk, and coordination with the patient’s medical team when appropriate.

Local anesthesia is standard for Ziplyft. Oral sedation is an option when appropriate. Medications such as Valium (diazepam), Ativan (lorazepam), or a similar oral anxiolytic may be used at the physician’s discretion and according to the practice’s usual protocols for patient comfort and safety.

No. The current Ziplyft device is intended for upper-eyelid treatment.

Osheru provides structured, hands-on training that combines technique review, device practice, and case-based instruction. Training covers marking, local anesthesia, device positioning and orientation, tissue capture, locking, compression, blade advancement and control, tissue excision, preparation for closure, tissue-adhesive application, inspection, and post-treatment care. Surgical videos and step-by-step technique resources are available for continued review.

Training can be tailored to the physician’s level of recent surgical experience. Additional time can be devoted to marking, symmetry, tissue handling, device positioning, closure, and hands-on practice before live treatment. Ziplyft does not replace surgical judgment; each physician should proceed only when comfortable with the technique and within the scope of their training and privileges.

Yes. Osheru’s implementation process is designed to prepare both the physician and the clinical team before the first treatment day. Support may include a supplies and logistics review, team workflow preparation, hands-on wet-lab practice, and onsite clinical support during the initial cases.

Ziplyft has a structured and repeatable workflow, but the technique should remain deliberate. Comfort develops through hands-on training and early clinical use, with particular attention to marking, complete tissue capture, full device locking, maintaining orientation, and controlled blade advancement.

Yes. Practice implementation includes clinical-team preparation in addition to hands-on physician training. Staff education covers the Ziplyft workflow, required supplies, room setup, treatment-day roles, patient education, post-treatment instructions, and follow-up. Physician training remains focused on clinical technique; staff preparation is focused on supporting the treatment confidently and consistently.

The team should confirm that the required supplies are available, understand treatment-day responsibilities, and be familiar with patient education, consent, skin-adhesive closure supplies, post-treatment instructions, and follow-up expectations. Osheru provides implementation materials and checklists to support this preparation.

• Request a Ziplyft device demonstration.
• Schedule physician training and hands-on technique review.
• Complete a brief practice implementation and supplies review with the clinical team.
• Coordinate the first treatment day and clinical support.

Combined clinical experience has shown an average bilateral Ziplyft treatment time of approximately 11 minutes, excluding preoperative marking and administration of anesthesia.

Ziplyft is designed to support an in-office eyelid treatment workflow. The procedure should be performed in an appropriate procedure setting that meets the physician’s practice protocols and applicable local requirements.

No. Sutures are not used for standard Ziplyft closure. After the treatment area is inspected and thoroughly dried, skin adhesive is applied to approximate and seal the incision.

No. Cautery is not used with the Ziplyft treatment. The device uses controlled compression before and after excision to support hemostasis and minimize bleeding.

Ziplyft is designed to support a quick recovery with limited downtime, helping patients return to their normal daily activities quickly. Swelling and bruising will still occur during the healing process, and the amount can vary from patient to patient. The compression-based, minimally invasive approach is designed to minimize bleeding, bruising, and swelling while supporting an efficient in-office recovery experience. The skin adhesive typically begins to peel naturally about five to seven days after treatment; patients should not pick at, touch, or attempt to remove the adhesive.

A 7–10 day post-treatment assessment is recommended to evaluate early healing, incision appearance, and wound integrity, with an additional follow-up at 1–2 months to assess continued healing and the treatment result. Additional follow-up should be based on the physician’s clinical judgment and the individual patient’s needs.

Ziplyft is a sterile, single-use device intended for one procedure only.

The current Ziplyft device is available in one size. The physician individualizes treatment by adjusting the amount of tissue captured within the device according to the patient’s anatomy and preoperative markings.

Ziplyft is designed to fit into an in-office procedure workflow using supplies many surgical practices already keep on hand. Osheru provides the practice with a list of basic supplies to have available, and that list is reviewed with the staff during the implementation call to help prepare the team for the physician's first treatment day.

Ziplyft is offered as a cash-pay treatment option. This allows the practice and patient to move forward without the insurance authorization, coverage requirements, claims submission, and reimbursement processes that can accompany insurance-based procedures. Practices establish their own patient fee for the Ziplyft treatment.